Vaccinex, Inc. Skyrocketed

Vaccinex, Inc. (VCNX:NASDAQ) soared at $1.1, representing a gain of 34.1%. The stock appeared on our News Catalysts scanner on Fri, Oct 06, 2023 at 10:06 AM in the 'BIOTECH' category. From Fri, Sep 22, 2023, the stock recorded 20.00% Up Days and 36.36% Green Days

About Vaccinex, Inc. (VCNX:NASDAQ)

Vaccinex Inc is a clinical-stage biotechnology company. It is engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. Its lead product candidate VX15 is in clinical development for the treatment of NSCLC, osteosarcoma and Huntington's disease and additional product candidates VX5 and VX25 are in earlier stages of development.